ABITEC Unveils Comprehensive Custom Lipid Synthesis Capabilities for LNP Therapeutics

ABITEC Corporation has expanded its custom synthesis capabilities to include high-purity lipids for lipid nanoparticle (LNP) therapeutics. The comprehensive bench-to-patient service offering will address key market challenges, including limited availability of cGMP-grade lipids and unpredictable lead times. LNP developers in pharma, biotech, and academia will now be able to efficiently overcome their toughest lipid chemistry challenges and drive their LNP therapeutics programs forward.

LNPs play a crucial role in the targeted delivery of vaccines and advanced therapies. However, LNP formulations require complex and ultrapure lipids, which can be difficult to design and acquire owing to limited availability of cGMP-grade lipids, a lack of tailored support, fragmented service provision, and unpredictable lead times.

ABITEC’s newly expanded offering directly addresses these challenges. With multiple GMP manufacturing facilities, an established global footprint, and a dedicated team of PhD chemists and scientists experienced in LNP therapy applications, ABITEC can now reliably deliver ultra-pure custom lipids from mg to kg scale, all from a single partner.

Jeff Walton, CEO of ABITEC, said, “This launch significantly expands ABITEC’s functional lipids manufacturing capabilities to include custom lipid synthesis for the formulations of LNPs and other highly functional drug delivery platforms and technologies. ABITEC customers can now access research-grade and cGMP lipids specifically designed to meet their unique applications requirements. We look forward to continually supporting our customers with advanced technologies to help overcome complex challenges and enable enhanced therapeutic outcomes.”

Dr. Donald Kelemen, Chief Scientific Officer, Pharmaceutical Sciences, ABITEC, added, “Acquiring Larodan AB in 2020 enhanced our portfolio with world-class lipid synthesis facilities at the Karolinska Institute, Stockholm, Sweden. Building on Larodan's 50-year legacy of producing ultra-pure lipid standards, our facilities are now an industry beacon of innovation and quality. With these facilities and a team of experienced PhD scientists, we’re optimally positioned to develop next-gen lipids for state-of-the-art drug formulations. Our continued investment and expansion underscore our commitment to pharmaceutical science innovation and delivering superior solutions to our global clients."